Karyopharm is moving toward a bankruptcy process, with Gamida Cell’s parent expected to place the lead bid in a court-supervised auction. The situation follows recent debt negotiations, including a forbearance deal intended to push back payment schedules. Separately, a report said Karyopharm plans to merge with Ayrmid—the company behind an attempted purchase of bluebird—reflecting how limited strategic options have narrowed for a commercial-stage blood cancer developer. Together, the disclosures highlight how balance-sheet strain is increasingly driving consolidation or auction outcomes in hematology drug development, where pipeline dilution risks can quickly compound financing challenges.